Nivolumab-Associated Cardiac Manifestation of Cutaneous T-Cell Lymphoma in a Patient With Concurrent Renal Cell Carcinoma Authors: Mohamed Ibrahim, Nitya Batra, Oluwatayo Adeoye, Michael Acevedo Monsanto, Ephraim Parent, David Li, Muhamad Alhaj Moustafa Published: 2026 ABSTRACT Cardiac involvement by cutaneous T-cell lymphoma is exceedingly rare and poses considerable diagnostic and therapeutic challenges. Immune checkpoint inhibitors targeting programmed cell death-1 have reported variable activity in T-cell lymphomas and have been associated with paradoxical progression in select cases. We report a 72-year-old man with longstanding indolent CD8-positive cutaneous T-cell lymphoma and metastatic renal cell carcinoma who developed myocardial infiltration by lymphoma after prolonged nivolumab therapy. Diagnosis was established by surgical cardiac biopsy reporting CD3-positive, CD8-positive, and CD30-negative T-cell lymphoma with clonal overlap with prior cutaneous disease. Given concern for paradoxical progression, therapy was transitioned to avelumab, an antiprogrammed death ligand-1 antibody. After nivolumab discontinuation and transition to avelumab, the patient experienced complete metabolic resolution of cardiac involvement, improvement in cardiac biomarkers, and durable control of cutaneous lymphoma over more than 3 years of follow-up. This case highlights a temporal association between programmed cell death-1 blockade and atypical dissemination of cutaneous T-cell lymphoma, supported by biologic plausibility, and underscores a potential therapeutic distinction between programmed cell death-1 and programmed death ligand-1 inhibition in malignant T-cell disorders. Cutaneous T-cell lymphomas (CTCLs) are a rare subset of non-Hodgkin lymphomas, with advanced disease occasionally manifesting as visceral organ involvement. Cardiac involvement is exceptionally rare and notably absent from the list of commonly involved extracutaneous organs in autopsy series; to our knowledge, only isolated case reports have been documented in the literature.1, 2, 3, 4, 5 Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis, such as nivolumab, have expanded therapeutic options across multiple malignancies, but their use in T-cell lymphomas is complicated by the unique biology of these diseases, including the potential for paradoxical progression and atypical dissemination.6,7 Cardiac involvement by T-cell lymphoma is associated with poor prognosis and diagnostic difficulty, often requiring advanced imaging and tissue biopsy for confirmation.5,8 Recent advances in immunotherapy, including anti-PD–L1 agents such as avelumab, offer potential therapeutic options in select lymphoma contexts through immune modulation and antibody-dependent cell-mediated cytotoxicity, particularly when conventional strategies are limited.7 This case highlights the mechanistic interplay between immune checkpoint modulation and T-cell lymphoma biology, and the therapeutic implications of switching from anti-PD–1 to anti-PD–L1 therapy in the context of cardiac infiltration. Cardiac involvement in patients receiving ICIs presents a diagnostic challenge, as immune-mediated myocarditis, infection, and malignant myocardial infiltration may present with overlapping clinical features. Case Presentation A 72-year-old man with a history of multiple malignancies, including clear cell renal cell carcinoma (RCC) treated with left nephrectomy; papillary thyroid carcinoma treated with thyroidectomy and radioactive iodine; and a longstanding atypical indolent cutaneous CD3-positive, CD8-positive, CD30-negative epidermotropic T-cell lymphoma confined to the skin (Figure 1A), was followed in our clinic. The CTCL was diagnosed 10 years before this presentation. Clinically, CTCL presented as waxing and waning ulcerations limited to the skin and never required systemic therapy. He also carried a history of hypertension, mild aortic stenosis, and prior arrhythmia.Figure 1Histopathologic and Immunophenotypic Features of Cutaneous and Cardiac Involvement by Cutaneous T-cell Lymphoma. Prior skin biopsy from the right arm reporting a superficial dermal lymphocytic infiltrate with prominent epidermotropism, consistent with CTCL (Panel A). Cardiac biopsy reporting dense interstitial lymphoid infiltrates between myocardial fibers, confirming myocardial involvement by CTCL (Panel B). Immunohistochemistry reporting CD3 positivity in the infiltrating lymphocytes (Panel C) and CD8 positivity in the malignant T-cell population (Panel D). Histopathologic and Immunophenotypic Features of Cutaneous and Cardiac Involvement by Cutaneous T-cell Lymphoma. Prior skin biopsy from the right arm reporting a superficial dermal lymphocytic infiltrate with prominent epidermotropism, consistent with CTCL (Panel A). Cardiac biopsy reporting dense interstitial lymphoid infiltrates between myocardial fibers, confirming myocardial involvement by CTCL (Panel B). Immunohistochemistry reporting CD3 positivity in the infiltrating lymphocytes (Panel C) and CD8 positivity in the malignant T-cell population (Panel D). Routine surveillance imaging revealed a new pulmonary mass in the left lower lobe, and biopsy confirmed metastatic clear cell RCC. At the time of RCC recurrence, the patient’s CTCL had remained clinically indolent and confined to cutaneous sites for ∼10 years, had not required systemic therapy, and had no known clinical or radiographic evidence of extracutaneous involvement. He was initially started on the tyrosine kinase inhibitor pazopanib; however, treatment was discontinued due to hypertension and hand-foot syndrome. Nivolumab monotherapy was then selected as systemic therapy for metastatic RCC after pazopanib intolerance. After ∼2 years of nivolumab therapy, surveillance imaging identified a new mass extending along the interatrial septum and right and left atrioventricular grooves with extensive infiltrative myocardial involvement. Positron emission tomography (PET)/computed tomography (CT) reported intense fluorodeoxyglucose (FDG) uptake in the right atrioventricular groove with maximum standardized uptake value of 14.2 and a total lesion glycolysis of 685 (Figure 2A). Cardiac biomarkers were elevated, with troponin-T measuring 40 ng/L and NT-proBNP measuring 1393 pg/mL. Transthoracic echocardiography revealed a preserved left ventricular ejection fraction of 63% but a moderate pericardial effusion without tamponade physiology. Cardiac magnetic resonance imaging was not performed, as the presence of a focal hypermetabolic infiltrative cardiac mass on PET/CT prompted tissue-directed diagnostic evaluation. Several initial minimally invasive biopsy attempts, including endomyocardial and transesophageal-guided approaches, were nondiagnostic due to inadequate tissue sampling and showed only scant fibrous tissue, blood clots, adipose tissue, and chronic inflammation without definitive evidence of malignancy. Ultimately, a right mini-thoracotomy with excisional biopsy was performed. At the same operative evaluation, a right axillary skin lesion was also biopsied. There were no documented active CTCL lesions directly overlying the cardiac mass before detection of cardiac involvement. Histopathology reported diffuse myocardial infiltration by an atypical CD3-positive, CD8-positive, CD30-negative T-cell lymphoma with morphologic and immunophenotypic features similar to the patient’s prior epidermotropic CTCL and concurrent right axillary skin lesion (Figure 1B-D). T-cell receptor gene rearrangement studies confirmed clonality in the cardiac specimen that overlapped with the patient’s prior skin biopsies and concurrent right axillary skin lesion. These histopathologic, immunophenotypic, and molecular findings supported malignant myocardial infiltration by CTCL rather than ICI-associated myocarditis. Bone marrow evaluation performed after cardiac involvement was identified was focally suspicious for marrow infiltration by CTCL, with flow cytometry reporting increased CD8-positive T lymphocytes, a flipped CD4:CD8 ratio, and partially diminished CD5 and CD7 expression. At that time, marrow involvement was not associated with clinically relevant cytopenias, with a white blood cell count of 6.99 × 103/μL, hemoglobin of 13.3 g/dL, and platelet count of 204 × 103/μL. Immunohistochemistry did not report relevant PD-L1 expression on the malignant T-cell population. A concurrent biopsy of the RCC metastasis showed absence of PD-L1 expression.Figure 2Longitudinal FDG-PET/CT imaging reporting cardiac involvement of cutaneous T-cell lymphoma and treatment response. Axial fused FDG-PET/CT images at initial diagnosis (Panel A) show intense focal FDG uptake along the right atrioventricular groove (arrow), consistent with biopsy-proven cardiac involvement by CTCL. At 5 months post treatment (Panel B), the previously identified atrioventricular groove mass and focal uptake have resolved (arrow), with overall reduction in cardiac metabolic activity and mild residual uptake at the ventricular apex and tricuspid valve (Deauville score 4). Maximum intensity projection images (Panel C) at initial diagnosis, 5 months post treatment, and 4 years later report marked reduction in diffuse hypermetabolic cutaneous and soft tissue disease burden with sustained metabolic response on long-term follow-up. Longitudinal FDG-PET/CT imaging reporting cardiac involvement of cutaneous T-cell lymphoma and treatment response. Axial fused FDG-PET/CT images at initial diagnosis (Panel A) show intense focal FDG uptake along the right atrioventricular groove (arrow), consistent with biopsy-proven cardiac involvement by CTCL. At 5 months post treatment (Panel B), the previously identified atrioventricular groove mass and focal uptake have resolved (arrow), with overall reduction in cardiac metabolic activity and mild residual uptake at the ventricular apex and tricuspid valve (Deauville score 4). Maximum intensity projection images (Panel C) at initial diagnosis, 5 months post treatment, and 4 years later report marked reduction in diffuse hypermetabolic cutaneous and soft tissue disease burden with sustained metabolic response on long-term follow-up. Nivolumab was discontinued during the diagnostic evaluation of the cardiac mass. Given the unexpected systemic dissemination of CTCL with cardiac and marrow involvement, coupled with the patient’s ongoing metastatic RCC, therapeutic decision-making was complex. He was not considered a candidate for autologous or allogeneic stem cell transplantation due to his concurrent metastatic RCC. A multidisciplinary tumor board recommended systemic therapy with avelumab, an anti-PD–L1 ICI, on the basis of its prior regulatory use in RCC and potential activity against T-cell lymphoma. This decision was further supported by concern that continued PD-1 blockade could be associated with ongoing lymphoma progression, and avelumab was initiated approximately 3 months after nivolumab discontinuation. The patient tolerated therapy well. After 4 cycles of avelumab, restaging PET/CT reported interval decrease in FDG activity in the myocardium, with maximum standardized uptake value decreasing to 12 and total lesion glycolysis declining to 552. After 8 cycles, a repeat PET/CT showed no atrioventricular groove mass or FDG uptake (Figure 2B). The pericardial effusion resolved, and cardiac biomarkers improved, with NT-proBNP decreasing to 436 pg/mL and troponin-T to 10 ng/L. Clinically, he reported no chest pain, palpitations, or dyspnea, and functional status remained preserved. Subsequent serial PET/CT scans reported durable suppression of myocardial uptake and decreased recurrence of new cutaneous lesions. Over the next 3 years of follow-up, the CTCL remained well controlled on continuous avelumab, which he continues to receive without major immune-related adverse events. During this period, avelumab was continued without interruption. The patient’s metastatic RCC was initially monitored while cardiac and cutaneous CTCL remained controlled. More than 1 year after avelumab initiation, RCC progression was identified with development of osseous metastatic disease. Cabozantinib was recommended after completion of local radiotherapy and was ultimately initiated approximately 21 months after avelumab initiation after blood pressure optimization. Cabozantinib was given concurrently with ongoing avelumab, initially at 20 mg daily with later escalation to 40 mg daily in response to RCC progression. Serial imaging reported waxing and waning RCC, with periods of partial response interspersed with slow progression. He underwent stereotactic radiotherapy to selected oligoprogressive osseous and soft tissue RCC lesions, which provided additional local control. Functionally, the patient remained active with an Eastern Cooperative Oncology Group performance status of 1. He required a cane or walker for ambulation, primarily due to hip pain related to osseous metastases and orthopedic hardware. As of the most recent follow-up, more than 3 years after initiation of avelumab and over 100 cycles, the patient remains on active therapy with stable cardiac disease and very well controlled skin manifestations of CTCL and manageable RCC activity. Serial PET/CT scans continue to report improved FDG uptake within the myocardium, absence of pericardial effusion, and no new cutaneous or systemic lymphoma involvement (Figure 2C). His RCC reports indolent progression, managed with cabozantinib and focal radiotherapy. He continues to tolerate therapy, with manageable treatment-related toxicities. Discussion The cardiac involvement of CTCL in this patient after nivolumab therapy is a rare and clinically significant event, with cardiac infiltration by lymphoma accounting for a small fraction of extranodal lymphomas and most commonly affecting the right atrium and pericardium.5 In a retrospective analysis of 37 cases of cardiac lymphoma encompassing mixed histologies, predominantly diffuse large B-cell lymphoma, only 3 patients had discrete solid cardiac masses, while most presented with pericardial effusion and advanced-stage systemic disease.5 T-cell lymphomas, including CTCL, are highly heterogeneous and often present with extranodal involvement in advanced stages, where outcomes are poor.4 Immune checkpoint inhibition with PD-1 blockade has been investigated in CTCL with overall modest and heterogeneous clinical activity. Early-phase studies of nivolumab in relapsed or refractory hematologic malignancies that included patients with mycosis fungoides and Sézary syndrome reported objective responses in a minority of patients with CTCL, with most responses being partial and of limited durability.9 In these cohorts, progression-free survival was short, and a substantial proportion of patients experienced primary refractory disease or early progression, highlighting the limited efficacy of PD-1 inhibition as monotherapy in CTCL.9 Subsequent phase II studies of PD-1 blockade in CTCL, including trials of pembrolizumab, have reported an objective response rate of 38% with most responses being partial and a median progression-free survival measured in months.10 There was also transient worsening of erythroderma and pruritus in 53% of patients with Sézary syndrome along with frequent disease relapse, reinforcing the variability and limited durability of checkpoint inhibitor responses in this disease.10 Importantly, correlative analyses from these studies suggest that response to PD-1 blockade in CTCL is not reliably predicted by PD-1 or PD-L1 expression and may reflect complex tumor-intrinsic and microenvironmental factors unique to malignant T cells.10 Preclinical and translational data indicate that PD-1 may function as an intrinsic negative regulator of proliferation in malignant T-cell lymphomas, including CTCL, raising concern that PD-1 blockade may paradoxically promote disease acceleration or atypical dissemination in select patients.6,7,11 Clinical reports and review-level analyses describing disease flare, rapid cutaneous progression, and visceral involvement after PD-1 inhibitor exposure in CTCL further support this biologic model.7 In the present case, the development of systemic CTCL with myocardial and bone marrow involvement after prolonged nivolumab therapy is consistent with these observations and underscores the need for careful patient selection and vigilant monitoring when considering PD-1 blockade in CTCL. Cardiac toxicities associated with ICIs, including myocarditis, pericardial effusion, and arrhythmias, are increasingly recognized, with an incidence of 0.5%-1.14% and mortality rates of 25%-50% in fulminant cases.12, 13, 14 The pathophysiology involves autoreactive T-cell activation, immune-mediated inflammation, and myocardial injury, with elevated cardiac biomarkers and imaging findings supporting the diagnosis.12, 13, 14 The National Comprehensive Cancer Network recommends early recognition, biomarker monitoring, and multidisciplinary management for ICI-associated cardiac immune-related adverse events.12 In this patient, the diagnosis of ICI-associated myocarditis was considered because of prior nivolumab exposure, elevated cardiac biomarkers, pericardial effusion, and infiltrative cardiac findings. However, the definitive surgical biopsy reported dense atypical T-cell infiltration with immunophenotypic and molecular concordance with the patient’s known CTCL and concurrent skin lesion, supporting malignant myocardial infiltration rather than classic immune-mediated myocarditis.5 Cardiac magnetic resonance imaging can support the diagnosis of ICI-associated myocarditis by reporting myocardial edema and nonischemic late gadolinium enhancement, although findings may be variable and can overlap with other inflammatory or infiltrative processes.12, 13, 14 In contrast, cardiac lymphoma more often presents as a focal or infiltrative mass, frequently with pericardial involvement or FDG avidity on PET/CT, but imaging alone cannot reliably establish lineage or distinguish malignant infiltration from immune-mediated inflammation.5,8 Therefore, in this case, tissue diagnosis was essential to distinguish CTCL involvement from ICI-associated myocarditis. Standard treatment for CTCL depends on disease stage, symptom burden, and extent of extracutaneous involvement. Skin-limited disease is generally managed with skin-directed therapies, including topical corticosteroids, phototherapy, topical retinoids, topical chemotherapy, or local radiation.4 Advanced, refractory, or extracutaneous disease may require systemic therapy, including retinoids, interferon, histone deacetylase inhibitors, mogamulizumab, brentuximab vedotin in CD30-expressing disease, chemotherapy, localized radiation for symptomatic sites, or stem cell transplantation in selected candidates.4 In this patient, treatment selection was constrained by CD30-negative disease, cardiac involvement, suspected marrow involvement, concurrent metastatic RCC, and ineligibility for autologous or allogeneic stem cell transplantation. Avelumab is not a standard therapy for CTCL. In this case, it was selected primarily to maintain immunotherapeutic activity against metastatic RCC while avoiding continued PD-1 blockade, with additional hypothesis-generating rationale based on PD-L1 inhibition, tumor microenvironment modulation, and antibody-dependent cell-mediated cytotoxicity.7 Unlike PD-1 inhibitors, anti-PD–L1 agents block ligand interaction without directly inhibiting PD-1 signaling on malignant T cells, a distinction that may be relevant in malignant T-cell disorders but remains unproven clinically.7 Although PD-L1 expression was not detected on the malignant T-cell population in this case, PD-L1 blockade may still exert antitumor effects through modulation of the tumor microenvironment, inhibition of PD-L1-expressing antigen-presenting cells, and antibody-dependent cell-mediated cytotoxicity.7 Notably, absence of PD-L1 expression on malignant cells does not necessarily preclude clinical benefit from PD-L1 blockade, given its effects on the tumor microenvironment and immune effector mechanisms. In early-phase clinical studies, avelumab reported activity in select lymphoma subtypes, with an overall response rate of 38% (complete response rate 24%) in relapsed/refractory extranodal NK/T-cell lymphoma and 42% in relapsed/refractory classical Hodgkin lymphoma, with a generally favorable safety profile.15,16 In this context, transition to PD-L1 blockade was followed by durable control of cardiac CTCL while also maintaining immunotherapeutic activity against metastatic RCC; however, this observation remains hypothesis generating and should not be interpreted as establishing PD-L1 blockade as a standard therapy for CTCL. In summary, the progression of T-cell lymphoma with cardiac infiltration after nivolumab therapy is consistent with mechanistic and translational studies suggesting a risk of paradoxical progression and organ dissemination during PD-1 blockade.7 The subsequent improvement after transition to avelumab may be related to nivolumab discontinuation, immune modulation without direct PD-1 inhibition, antibody-dependent cell-mediated cytotoxicity, or a combination of these factors.7 Because nivolumab discontinuation and avelumab initiation occurred within the same clinical sequence, their relative contributions cannot be definitively separated. This case underscores the importance of individualized therapy selection, vigilant monitoring for immune-related toxicities, and multidisciplinary management in patients with advanced CTCL and atypical organ involvement.4,12 Interpretation of this case is limited by its single-patient nature and the inability to definitively establish causality between PD-1 blockade and lymphoma progression. Conclusion Cardiac infiltration by cutaneous T-cell lymphoma after nivolumab therapy represents a rare but clinically relevant event and may reflect a temporal association between PD-1 blockade and systemic CTCL progression, supported by the unique biology of malignant T cells.5, 6, 7 In this context, inhibition of PD-1 may remove intrinsic inhibitory signaling on malignant T cells, providing a biologically plausible mechanism for aggressive dissemination and visceral involvement in select cases. Transition to PD-L1 blockade with avelumab achieved durable clinical and radiographic disease control through alternative immune mechanisms without direct stimulation of malignant T-cell proliferation, while also providing therapeutic benefit for concurrent metastatic RCC. This case highlights the importance of careful checkpoint selection, vigilant monitoring, and individualized immunotherapeutic strategies in patients with CTCL receiving ICIs. Potential Competing Interests The authors declare that they have no conflicts of interest relevant to this case report. Ethics Statement Informed consent was obtained from the patient for publication of this case report and accompanying images. All identifying information was removed to protect patient confidentiality, and ethical approval was not required for this single-patient case report according to institutional policy.